Thermo Fisher Scientific is a global leader in providing scientific instruments, reagents, and consumables, with a focus on advancing healthcare, life sciences, and laboratory workflows. The company supports a diverse range of customers, including researchers, clinical laboratories, and pharmaceutical companies, by offering innovative solutions that enable breakthroughs in areas such as diagnostics, drug development, and environmental analysis. With a commitment to quality and efficiency, Thermo Fisher Scientific plays a crucial role in enhancing productivity and scientific discovery across various disciplines while promoting better health outcomes worldwide. Read More
Life sciences company Thermo Fisher (NYSE:TMO) reported revenue ahead of Wall Street’s expectations in Q3 CY2025, with sales up 4.9% year on year to $11.12 billion. Its non-GAAP profit of $5.79 per share was 5.3% above analysts’ consensus estimates.
Washington D.C., October 22, 2025 – Danaher Corporation (NYSE: DHR) is currently experiencing a wave of positive sentiment, with its stock price widely expected to rise following a robust third-quarter 2025 earnings report. The life sciences and diagnostics giant exceeded analyst expectations, fueling an optimistic outlook from market experts and
Risk sentiment deteriorated sharply on Wednesday as a wave of disappointing earnings guidance and escalating U.S.-China trade tensions rattled investor confidence.
Life sciences company Thermo Fisher (NYSE:TMO) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 4.9% year on year to $11.12 billion. Its non-GAAP profit of $5.79 per share was 5.3% above analysts’ consensus estimates.
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the third quarter ended September 27, 2025.
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced plans to further increase the impact of Thermo Fisher’s proven growth strategy through the use of artificial intelligence (AI) with OpenAI. This collaboration will help to improve the speed and success of drug development, enabling customers to get medicines to patients faster and more cost effectively.
October 14, 2025 -- Partnership integrates Axiom™ microarray data with real-time clinical decision support to advance precision medicine at the point of care.
